Nurse Practitioner · Wyomissing, PA
NPI
1174580716
Since 2006
Specialty
Nurse Practitioner
Code 363L00000X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
1030 Reed Ave, Suite 116
Wyomissing, PA, 19610
Phone (610) 373-7743
Groups this clinician bills Medicare through
Medicare paid, 2024
$108K
1,786 services
Medicare patients, 2024
522
Average age 74
Drug cost, 2024
$5.5M
7,759 prescriptions
Company payments, 2025
$2,377
From 20 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Ralph M Cincinnati was code 99214 (office e&m - established), 1,259 times for 502 patients. In total Ralph M Cincinnati billed 1,786 services in 6 codes, and Medicare paid $108K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2015-10-04.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 1,259 | 502 | $67.77 | $85K |
| 95251 Test - Miscellaneous | Office | 440 | 192 | $19.46 | $8,560 |
| 99213 Office E&M - Established | Office | 59 | 44 | $50.02 | $2,951 |
| 99204 Office E&M - New | Office | 22 | 22 | $85.05 | $1,871 |
By year: 2022 $137K for 1,997 services; 2023 $123K for 1,836 services; 2024 $108K for 1,786 services.
Medicare prescription drug claims, 2024
In 2024, the drug Ralph M Cincinnati prescribed most often to Medicare patients was Ozempic (Semaglutide), with 525 prescriptions and refills. In total Ralph M Cincinnati wrote 7,759 Medicare prescriptions that cost $5.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ozempic Semaglutide | 525 | 935 | 113 | $882K |
| Glimepiride Generic | 459 | 1,288 | 130 | $6,369 |
| Metformin Hcl Generic | 447 | 1,273 | 130 | $4,016 |
| Mounjaro Tirzepatide | 439 | 555 | 83 | $573K |
| Levothyroxine Sodium Generic | 387 | 1,048 | 104 | $4,088 |
| Jardiance Empagliflozin | 327 | 661 | 80 | $376K |
| Tresiba Flextouch U-200 Insulin Degludec | 294 | 718 | 86 | $340K |
| Farxiga Dapagliflozin Propanediol | 265 | 542 | 60 | $292K |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 252 | 608 | 81 | $39K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 234 | 636 | 96 | $31K |
| Novolog Flexpen Insulin Aspart | 232 | 458 | 73 | $52K |
| Glyxambi Empagliflozin/Linagliptin | 213 | 353 | 40 | $199K |
| Humalog Kwikpen U-100 Insulin Lispro | 144 | 326 | 47 | $47K |
| Trulicity Dulaglutide | 139 | 264 | 34 | $255K |
| Tradjenta Linagliptin | 136 | 318 | 38 | $155K |
Brand drugs: 4,642 claims; generic drugs: 2,450 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Ralph M Cincinnati $2,377 ($2,377 in general payments such as food, travel and fees) from 20 companies. The largest payer was Abbott Laboratories with $340.
| Company | Payments | Amount |
|---|---|---|
| Abbott Laboratories ABT | 12 | $340 |
| Novo Nordisk Inc NVO | 13 | $274 |
| Abbvie Inc. ABBV | 13 | $271 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 6 | $156 |
| Lilly USA, LLC LLY | 8 | $153 |
| Amgen Inc. AMGN | 18 | $151 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 6 | $113 |
| Mannkind Corporation MNKD | 4 | $112 |
| Corcept Therapeutics CORT | 6 | $111 |
| Insulet Corporation PODD | 3 | $111 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.